JP2005508337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508337A5 JP2005508337A5 JP2003530699A JP2003530699A JP2005508337A5 JP 2005508337 A5 JP2005508337 A5 JP 2005508337A5 JP 2003530699 A JP2003530699 A JP 2003530699A JP 2003530699 A JP2003530699 A JP 2003530699A JP 2005508337 A5 JP2005508337 A5 JP 2005508337A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- compound
- halogen
- physiologically functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052736 halogen Chemical group 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32601201P | 2001-09-27 | 2001-09-27 | |
| PCT/US2002/030150 WO2003027111A1 (en) | 2001-09-27 | 2002-09-24 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508337A JP2005508337A (ja) | 2005-03-31 |
| JP2005508337A5 true JP2005508337A5 (enExample) | 2005-12-22 |
Family
ID=23270442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530699A Pending JP2005508337A (ja) | 2001-09-27 | 2002-09-24 | 化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7015231B2 (enExample) |
| EP (1) | EP1430053B1 (enExample) |
| JP (1) | JP2005508337A (enExample) |
| AT (1) | ATE343575T1 (enExample) |
| DE (1) | DE60215682T2 (enExample) |
| ES (1) | ES2275021T3 (enExample) |
| WO (1) | WO2003027111A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7071217B2 (en) | 2000-09-01 | 2006-07-04 | Smithkline Beecham Corporation | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| WO2002020513A1 (en) | 2000-09-01 | 2002-03-14 | Glaxo Group Limited | Oxindole derivatives |
| US7015231B2 (en) * | 2001-09-27 | 2006-03-21 | Smithkline Beecham Corporation | Chemical compounds |
| DK2383268T3 (en) | 2005-02-04 | 2015-09-14 | Astrazeneca Ab | PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors |
| KR101362621B1 (ko) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | 화합물 |
| KR20070104936A (ko) * | 2005-02-16 | 2007-10-29 | 아스트라제네카 아베 | 화합물 |
| BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5182088B2 (ja) | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
| RU2016116516A (ru) * | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| JP5778755B2 (ja) * | 2010-04-15 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヒドロキノンの製造方法 |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| CN103804273B (zh) * | 2014-01-27 | 2016-06-15 | 贵州大学 | 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法 |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| CA2962206A1 (en) | 2014-09-17 | 2016-03-24 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| WO2019018570A1 (en) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB |
| WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9423997D0 (en) * | 1994-11-28 | 1995-01-11 | Erba Carlo Spa | Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| CA2383623A1 (en) * | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
| US7015231B2 (en) * | 2001-09-27 | 2006-03-21 | Smithkline Beecham Corporation | Chemical compounds |
-
2002
- 2002-09-24 US US10/490,831 patent/US7015231B2/en not_active Expired - Fee Related
- 2002-09-24 DE DE60215682T patent/DE60215682T2/de not_active Expired - Fee Related
- 2002-09-24 AT AT02799606T patent/ATE343575T1/de not_active IP Right Cessation
- 2002-09-24 JP JP2003530699A patent/JP2005508337A/ja active Pending
- 2002-09-24 WO PCT/US2002/030150 patent/WO2003027111A1/en not_active Ceased
- 2002-09-24 ES ES02799606T patent/ES2275021T3/es not_active Expired - Lifetime
- 2002-09-24 EP EP02799606A patent/EP1430053B1/en not_active Expired - Lifetime
-
2006
- 2006-01-20 US US11/336,010 patent/US20060128745A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523216A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| JP2023512175A5 (enExample) | ||
| JP2004517049A5 (enExample) | ||
| JP4959900B2 (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| JP2006526590A5 (enExample) | ||
| JP2004517099A5 (enExample) | ||
| JP2024540183A5 (enExample) | ||
| JP2006182786A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2021521118A5 (enExample) | ||
| JP2003503449A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2013540114A5 (enExample) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2004517098A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| JP2005513014A5 (enExample) | ||
| IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
| JP2005538974A5 (enExample) | ||
| JP2006516643A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| JP2008500378A5 (enExample) |